WO2015177758A1 - Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base - Google Patents

Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base Download PDF

Info

Publication number
WO2015177758A1
WO2015177758A1 PCT/IB2015/053765 IB2015053765W WO2015177758A1 WO 2015177758 A1 WO2015177758 A1 WO 2015177758A1 IB 2015053765 W IB2015053765 W IB 2015053765W WO 2015177758 A1 WO2015177758 A1 WO 2015177758A1
Authority
WO
WIPO (PCT)
Prior art keywords
cabozantinib
solvent
malate
process according
crystalline form
Prior art date
Application number
PCT/IB2015/053765
Other languages
French (fr)
Inventor
Ramakoteswara Rao Jetti
Anjaneyaraju Indukuri
Dnyandeo PUNDE
Chandersingh BOHRA
Mahesh Kumar GADAKAR
Vinayak Gore
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Priority to US15/313,191 priority Critical patent/US9815789B2/en
Priority to EP15728635.2A priority patent/EP3145913A1/en
Publication of WO2015177758A1 publication Critical patent/WO2015177758A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates generally to novel crystalline forms of cabozantinib (S)-malate, designated as form-Mi, M 2 , M 3 , and M 4 and novel crystalline forms of cabozantinib free base, form-Mi, M 2 and M 3 .
  • the present invention also relates to process for the preparation of crystalline forms of cabozantinib (S)-malate, designated as form-Mi, M 2 , M 3 , and M 4 and novel crystalline forms of cabozantinib free base, form-Mi, M 2 and M 3 as well as crystalline cabozantinib (S)-malate form N-l .
  • Cabozantinib (S)-malate chemically known as N-(4-(6, 7-dimethoxyquinolin-4-yloxy) phenyl)- N'-(4-fluorophenyl) cyclopropane- 1, 1 -dicarboxamide (S)-malate is structurally represented as Formula-I below.
  • Cabozantinib is marketed under the trade name COMETRIQ® by Exelixis, Inc. COMETRIQ® is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.
  • the present invention provides novel crystalline forms of cabozantinib (S)-malate and novel crystalline forms of cabozantinib free base.
  • One aspect of the present invention provides novel crystalline forms-Mi, M 2 , M 3 and M4 of cabozantinib (S)-malate.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib (S)-malate which includes the steps of:
  • step (a) a) dissolving cabozantinib (S)-malate in a solvent or mixture of solvents, b) adding the above solution of step (a) to non-polar solvent, and
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib (S)-malate which includes the steps of:
  • step (a) adding the above solution of step (a) to non-polar solvent, and
  • Another embodiment of the present invention a process for the preparation of crystalline form- Mi of cabozantinib (S)-malate which includes the steps of: a) dissolving cabozantinib (S)-malate in a polar solvent,
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-M 3 of cabozantinib (S)-malate which includes the steps of: a) dissolving cabozantinib (S)-malate in a polar solvent,
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-M 4 of cabozantinib (S)-malate which includes the steps of: a) dissolving cabozantinib base and (S)-malic acid in a solvent to create a solution, b) adding the solution to a non-polar solvent, and
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-M 4 of cabozantinib (S)-malate which includes the steps of: a) dissolving cabozantinib (S)-malate in an amide solvent,
  • Another aspect of the present invention provides novel crystalline forms-Mi, M 2 and M 3 of cabozantinib free base.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib free base which includes the steps of: a) dissolving cabozantinib (S)-malate in a solvent to create a solution,
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib free base which includes the steps of: a) dissolving cabozantinib (S)-malate in a solvent to create a solution,
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-M2 of cabozantinib free base which includes the steps of: a) dissolving cabozantinib in a solvent,
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-M3 of cabozantinib free base which includes the steps of: a) providing cabozantinib base in an ester solvent,
  • Yet another aspect of the present invention provides a process for the preparation of crystalline cabozantinib (S)-malate form N-l which includes the steps of: a) providing cabozantinib base and (S)-malic acid in a first polar solvent, b) adding second solvent,
  • FIGURE 1 is a powder X-ray diffraction pattern of crystalline cabozantinib (S)-malate form-Mi;
  • FIGURE 2 is a DSC thermogram of crystalline cabozantinib (S)-malate form-Mi;
  • FIGURE 3 is a TGA trace of crystalline cabozantinib (S)-malate form-Mi;
  • FIGURE 4 is a powder X-ray diffraction pattern of crystalline cabozantinib (S)-malate form-M 2
  • FIGURE 5 is a DSC thermogram of crystalline cabozantinib (S)-malate form-M 2 ;
  • FIGURE 6 is a TGA trace of crystalline cabozantinib (S)-malate form-M 2 ;
  • FIGURE 7 is a powder X-ray diffraction pattern of crystalline cabozantinib (S)-malate form-M 3 ;
  • FIGURE 8 is a powder X-ray diffraction pattern of crystalline cabozantinib (S)-malate form-Mt;
  • FIGURE 9 is a DSC thermogram of crystalline cabozantinib (S)-malate form-Mt;
  • FIGURE 10 is a TGA trace of crystalline cabozantinib (S)-malate form-Mt;
  • FIGURE 11 is a powder X-ray diffraction pattern of crystalline cabozantinib free base form-Mi;
  • FIGURE 12 is a DSC thermogram of crystalline cabozantinib free base form-Mi;
  • FIGURE 13 is a TGA trace of crystalline cabozantinib free base form-Mi;
  • FIGURE 14 is a powder X-ray diffraction pattern of crystalline cabozantinib free base form-M 2 ;
  • FIGURE 15 is a DSC thermogram of crystalline cabozantinib free base form-M 2 ;
  • FIGURE 16 is a TGA trace of crystalline cabozantinib free base form-M 2 ;
  • FIGURE 17 is a powder X-ray diffraction pattern of crystalline cabozantinib free base form-M3.
  • the present disclosure provides novel crystalline forms-Mi, M 2 , M3 and M4 of cabozantinib (S)- malate and crystalline forms-Mi, M 2 and M3 of cabozantinib free base.
  • the present disclosure also provides processed for the preparation of crystalline forms-Mi, M 2 , M3 and M4 of cabozantinib (S)-malate and crystalline forms-Mi, M 2 and M3 of cabozantinib free base as well as crystalline cabozantinib (S)-malate form N-l.
  • One aspect of the present invention provides crystalline form-Mi of cabozantinib (S)-malate.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib (S)-malate in a solvent to create a solution,
  • step (b) adding the above solution of step (a) to a non-polar solvent, and
  • cabozantinib (S)-malate may be dissolved in a solvent to create a solution.
  • the solvent used for dissolving cabozantinib (S)-malate may be, for example, ethereal, alcoholic, water, or mixtures thereof.
  • suitable ethereal solvents include dimethyl ether, diethyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
  • Suitable alcohols include, for example, methanol, ethanol, propanol, and butanol.
  • a mixture of tetrahydrofuran and water was found to be a particularly useful solvent for dissolving cabozantinib (S)-malate.
  • the solution of cabozantinib (S)-malate may be added to a non-polar solvent.
  • the non- polar solvent may be, for example, a Ci-Cio alkane or a mixture of Ci-Cio alkanes.
  • n-heptane was found to be a particularly useful non-polar solvent.
  • the obtained solid may then be isolated to get a crystalline form-Mi of cabozantinib (S)-malate.
  • cabozantinib (S)-malate may be dissolved in tetrahydrofuran and water at a temperature of about 55°C to about 70°C. The reaction temperature may then be cooled to room temperature. The resulting clear solution may then be added to a non-polar solvent such as n-heptane. The obtained solid may be filtered and dried to get the crystalline form-Mi of cabozantinib (S)-malate.
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib (S)-malate which includes the following steps:
  • step (a) a) dissolving cabozantinib base and (S)-malic acid in a solvent to create a solution, b) adding the above solution of step (a) to non-polar solvent, and
  • cabozantinib base and (S)-malic acid may be dissolved in a solvent.
  • the solvent may be, for example, an ethereal solvent, an alcoholic solvent, water, or a mixture thereof.
  • suitable ethereal solvents include dimethyl ether, diethyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
  • suitable alcohols include methanol, ethanol, propanol, and butanol. In some embodiments of the present invention, a mixture of tetrahydrofuran and water was found to be particularly useful.
  • tetrahydrofuran and water in a ratio of 12: 1 was found to be particularly useful.
  • the solution of cabozantinib (S)-malate may be added to a non-polar solvent.
  • the non- polar solvent may be, for example, a Ci-Cio alkane or a mixture of Ci-Cio alkanes.
  • n-heptane was found to be a particularly useful non-polar solvent.
  • the obtained solid may then be isolated to get a crystalline form-Mi of cabozantinib (S)-malate.
  • cabozantinib base and (S)-malic acid may be dissolved in a mixture of solvents such as tetrahydrofuran and water at a temperature between about 55°C to about 70°C. The temperature of the solution may then be cooled to room temperature. The resulting clear solution may then be added to non-polar solvent, for example, n-heptane, at about 20°C to about 35°C. The obtained solid may then be filtered and dried under vacuum to get the crystalline form-Mi of cabozantinib (S)-malate.
  • solvents such as tetrahydrofuran and water
  • the crystalline polymorph forms of compounds disclosed in the present invention may be characterized by X-ray powder diffraction ("XRPD") pattern.
  • XRPD X-ray powder diffraction
  • the XRPD patterns were measured on BRUKER D-8 Discover powder diffractometer equipped with goniometer of ⁇ /2 ⁇ configuration and Lynx Eye detector.
  • the Cu-anode X-ray tube was operated at 40kV and 30mA. The experiments were conducted over the 2 ⁇ range of 2.0°-50.0°, 0.030° step size and 0.4 seconds step time.
  • crystalline form-Mi of cabozantinib (S)-malate may be characterized by an XRPD pattern having characteristic peak at about 13.2 ( ⁇ ) 0.2° 2-theta.
  • the crystalline form-Mi of cabozantinib (S)-malate may be further characterized by the XRPD pattern in FIGURE 1.
  • the crystalline polymorph forms of compounds disclosed in the present invention may also be characterized by differential scanning calorimetry (DSC).
  • DSC differential scanning calorimetry
  • the DSC measurements were carried out on TA Q1000 of TA Instruments. The experiments were performed at a heating rate of 20.0 °C/min over a temperature range of 30°C-330°C purging with nitrogen at a flow rate of 50 ml/min. Standard aluminum crucibles covered by lids with pin holes were used.
  • the crystalline form-Mi of cabozantinib (S)-malate may be characterized by the DSC thermogram in FIGURE 2.
  • the crystalline polymorph forms of compounds disclosed in the present invention may also be characterized by thermogravimetric analysis (TGA).
  • TGA thermogravimetric analysis
  • TGA/DTA was recorded using the instrument TA Q5000 IR of TA Instruments. The experiments were performed at a heating rate of 10.0 °C/min over a temperature range of 30°C- 350°C purging with nitrogen at a flow rate of 25 ml/min.
  • the crystalline form-Mi of cabozantinib (S)-malate may be characterized by the TGA trace in FIGURE 3.
  • Another aspect of the present invention provides crystalline form-M 2 of cabozantinib (S)-malate.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-M 2 of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib (S)-malate in a polar solvent to create a solution,
  • cabozantinib (S)-malate may be dissolved in a polar solvent.
  • the polar solvent may be, for example, formic acid, acetic acid, or propionic acid.
  • propionic acid is a particularly useful solvent.
  • an ethereal solvent may be added to the reaction mass.
  • the ethereal solvent may be, for example, dimethyl ether, diethyl ether, ethyl methyl ether, methyl-t-butyl ether, tetrahydrofuran, or 1,4-dioxane.
  • methyl-t- butyl ether was found to be a particularly useful solvent. Crystalline form-M 2 of cabozantinib (S)-malate may then be isolated.
  • cabozantinib (S)-malate may be dissolved in a polar solvent such as propionic acid at temperature about 45°C to about 55°C and then cooled to about 20°C to about 35°C.
  • An ethereal solvent such as methyl-t-butyl ether may then be added to the reaction mixture.
  • the obtained solid may then be filtered and dried to get the crystalline form-M 2 of cabozantinib (S)-malate.
  • crystalline form-M 2 of cabozantinib (S)-malate may be characterized by the XRPD pattern having characteristic peaks at 8.5, 12.5, 20.2, 23.1, and 26.1 ( ⁇ ) 0.2° 2-theta.
  • crystalline form-M 2 of cabozantinib (S)-malate may be further characterized by XRPD pattern having characteristic peaks at 8.5, 12.5, 14.3, 20.2, 22.2, 23.1, 26.1, 26.6, and 26.9 ( ⁇ ) 0.2° 2-theta.
  • the crystalline form-M 2 of cabozantinib (S)-malate may be further characterized by the XRPD pattern in FIGURE 4.
  • the crystalline form-M 2 of cabozantinib (S)-malate may also be characterized by the DSC thermogram in FIGURE 5.
  • the crystalline form-M 2 of cabozantinib (S)-malate may additionally be characterized by the TGA trace in FIGURE 6.
  • Another aspect of the present invention provides crystalline form-M3 of cabozantinib (S)-malate.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-M 3 of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib (S)-malate in a polar solvent to create a solution,
  • cabozantinib (S)-malate may be dissolved in a polar solvent.
  • the polar solvent may be, for example, formic acid, acetic acid, or propionic acid.
  • acetic acid was found to be a particularly useful polar solvent.
  • cabozantinib (S)-malate may be dissolved in a polar solvent, such as acetic acid, at a temperature between about 55°C and about 65°C.
  • a polar solvent such as acetic acid
  • the resulting clear solution may be cooled to about -5°C to about 10°C, and water may be added to the reaction mass.
  • the obtained solid may then be filtered and washed with water to get the crystalline form-M3 of cabozantinib (S)-malate.
  • crystalline form-M3 of cabozantinib (S)-malate may be characterized by the XRPD pattern having characteristic peaks, 11.9, 12.6, and 18.1 ( ⁇ ) 0.2° 2- theta.
  • crystalline form-M3 of cabozantinib (S)-malate may be further characterized by the XRPD pattern having characteristic peaks at 6.3, 9.1, 11.9, 12.6, 13.6, 15.1, 16.9, 18.1, 19.1, 21.2, 23.7, 25.8, 27.5, 30.1 , and 31.0 ( ⁇ ) 0.2° 2-theta.
  • the crystalline form- M 3 of cabozantinib (S)-malate may also be further characterized by the powder X-ray diffractogram in FIGURE 7.
  • Another aspect of the present invention provides the crystalline form-Mi of cabozantinib (S)- malate.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-M 4 of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib base and (S)-malic acid in a solvent to create a solution, b) adding the above solution of step (a) to a non-polar solvent,
  • cabozantinib base and (S)-malic acid may be dissolved in a solvent.
  • the solvent may be, for example, an ethereal solvent, an alcoholic solvent, water, or a mixture thereof.
  • suitable ethereal solvents include dimethyl ether, diethyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
  • Suitable alcohols include, for example, methanol, ethanol, propanol, and butanol.
  • a mixture of tetrahydrofuran and water was found to be particularly useful.
  • a ratio of 15: 1 tetrahydrofuran to water was found to be particularly useful.
  • the solution of cabozantinib (S)-malate may be added to a non-polar solvent.
  • the non- polar solvent may be, for example, a Ci-Cio alkane or a mixture of Ci-Cio alkanes.
  • n-heptane was found to be a particularly useful non-polar solvent.
  • the obtained solid may then be isolated to get a crystalline form-Mi of cabozantinib (S)-malate.
  • cabozantinib base and (S)-malic acid may be dissolved in a mixture of solvents, such as tetrahydrofuran and water, at a temperature between about 55°C and about 70°C.
  • the reaction temperature may then be cooled to room temperature.
  • the resulted clear solution may then be added to a non-polar solvent, for example, n-heptane, at about 45°C to about 60°C.
  • the resulted reaction mass may be cooled to about 20°C to about 35°C.
  • the obtained solid is filtered and dried under vacuum to get the crystalline form-M 4 of cabozantinib (S)-malate.
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-M 4 of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib (S)-malate in an amide solvent to create a solution, b) adding a solvent to the solution, and
  • cabozantinib (S)-malate may be dissolved in an amide solvent to create a solution.
  • the amide solvent may be, for example, N,N-dimethylacetamide, ⁇ , ⁇ -dimethylformamide, or N-methylpyrrolidone.
  • ⁇ , ⁇ -dimethylacetamide was found to be a particularly useful solvent.
  • a solvent may be added to the solution.
  • the solvent may be, for example, an ethereal solvent, an alcoholic solvent, water, or mixtures thereof.
  • Suitable ethereal solvents include dimethyl ether, diethyl ether, ethyl methyl ether, methyl-t-butyl ether, tetrahydrofuran, and 1,4-dioxane.
  • suitable alcohol solvents include methanol, ethanol, propanol, and butanol. In some embodiments, a mixture of methyl-t- butyl ether and ethanol was found to be particularly useful.
  • the solid may be isolated to get a crystalline form-Mi of cabozantinib (S)-malate.
  • cabozantinib (S)-malate may be dissolved in an amide solvent such as ⁇ , ⁇ -dimethylacetamide at a temperature between about 45°C and about 55°C to create a clear solution.
  • Methyl-t-butyl ether and ethanol may then be added to the clear solution at room temperature.
  • the obtained solid may then be filtered and dried to get the crystalline form-Mi of cabozantinib (S)-malate.
  • crystalline form-M 4 of cabozantinib (S)-malate may be characterized by the XRPD pattern having characteristic peaks at about 13.3, 15.0, 22.8, and 25.8 ( ⁇ ) 0.2° 2-theta.
  • the crystalline form-M t of cabozantinib (S)-malate may be further characterized by the XRPD pattern having characteristic peaks at 9.3, 13.3, 15.0, 19.5, 20.9, 22.8, 25.8, and 26.9 ( ⁇ ) 0.2° 2- theta.
  • the crystalline form-Mi of cabozantinib (S)-malate may also be characterized by the PXRD pattern in FIGURE 8.
  • the crystalline form-Mi of cabozantinib (S)-malate may be additionally characterized by the DSC thermogram in FIGURE 9.
  • the crystalline form-Mi of cabozantinib (S)-malate may be characterized by the TGA trace in FIGURE 10.
  • Another aspect of the present invention provides the novel crystalline form-Mi of cabozantinib free base.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib free base which includes the following steps: a) dissolving cabozantinib (S)-malate in a solvent to create a solution,
  • cabozantinib (S)-malate may be dissolved in a solvent to create a solution.
  • the solvent may be, for example, ⁇ , ⁇ -dimethylacetamide, N,N-dimethylformamide, N-methyl-2-pyrrolidone, dimethyl sulfoxide, acetonitrile, dichloromethane, tetrahydrofuran, or ethyl acetate.
  • N-methyl-2-pyrrolidone was found to be a particularly useful solvent.
  • ketone solvent may be, for example, acetone, methyl ethyl ketone, or methyl isobutyl ketone. In some embodiments of the present invention, acetone was found to be a particularly useful solvent.
  • crystalline form-Mi of cabozantinib free base may then be isolated.
  • cabozantinib (S)-malate may be dissolved in a solvent, such as N-methyl-2-pyrrolidone, at a temperature between about 20°C and about 35°C. Water may then be added to the clear solution. Next, a ketone solvent, for example, acetone, may be added, and the reaction mixture heated to about 45°C to about 55°C. Water may then be added while the reaction mixture is maintained at a temperature between about 20°C and about 35°C. The obtained solid may then be filtered to get the crystalline form-Mi of cabozantinib free base.
  • a solvent such as N-methyl-2-pyrrolidone
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib free base, which includes the following steps: a) dissolving cabozantinib (S)-malate in a solvent to form a solution,
  • cabozantinib (S)-malate may be dissolved in a solvent to create a solution.
  • the solvent may be, for example, ⁇ , ⁇ -dimethylacetamide, N,N- dimethylformamide, N-methyl-2-pyrrolidone, dimethyl sulfoxide, acetonitrile, dichloromethane, tetrahydrofuran, or ethyl acetate.
  • dimethyl sulfoxide was found to be a particularly useful solvent.
  • cabozantinib (S)-malate may be dissolved in a solvent, for example, in dimethyl sulfoxide, at a temperature of about 20°C to about 35°C. Water may then be added and the obtained solid is filtered to get the crystalline form-Mi of cabozantinib free base.
  • crystalline form-Mi of cabozantinib free base may be characterized by the XRPD pattern having peaks at about 11.8 ( ⁇ ) 0.2° 2-theta.
  • crystalline form-Mi of cabozantinib free base may be further characterized by the XRPD pattern having peaks at about 11.8, 12.8, 14.3, 17.8, and 22.7 ( ⁇ ) 0.2° 2-theta
  • the crystalline form-Mi of cabozantinib free base may be further characterized by the XRPD pattern as depicted in FIGURE 11.
  • the crystalline form-Mi of cabozantinib free base may be characterized by the DSC thermogram in FIGURE 12.
  • the crystalline form-Mi of cabozantinib free base may also be characterized by the TGA trace in FIGURE 13.
  • Another aspect of the present invention provides the novel crystalline form-M 2 of cabozantinib free base.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-M 2 of cabozantinib free base which includes the following steps: a) dissolving cabozantinib in a solvent,
  • cabozantinib may be dissolved in a solvent.
  • the solvent may be, for example, halogenated, alcoholic, or a mixture thereof.
  • Suitable halogenated solvents include, for example, dichloromethane and dichloroethane.
  • Suitable alcohols include, for example, methanol, ethanol, propanol, and butanol. In some embodiments of the present invention, a mixture of methanol and dichloromethane was found to be particularly useful.
  • some of the solvent is removed, for example by Evaporation, Heating and Distillation, preferably Distillation.
  • cabozantinib may be dissolved in a mixture of solvents, for example a mixture methanol and dichloromethane, at about 25°C to about 45°C.
  • a mixture of solvents for example a mixture methanol and dichloromethane
  • the resulting clear solution may then be partially distilled out under atmospheric pressure to obtain a slurry.
  • the slurry is then cooled to a temperature between about 20 °C and about 35 °C and filtered to get the crystalline form-M 2 of cabozantinib free base.
  • crystalline form-M 2 of cabozantinib free base may be characterized by the XRPD pattern having peaks at about 12.6, 14.1, 18.5, 22.1, 23.2, 24.1, and 29.0 ( ⁇ ) 0.2° 2-theta.
  • the crystalline form-M 2 of cabozantinib free base may further characterized by the XRPD pattern having peaks at about 7.8, 11.1, 11.5, 12.6, 14.1, 15.4, 17.2, 18.5, 19.2, 21.1, 22.1, 23.2, 24.1, and 29.0 ( ⁇ ) 0.2° 2-theta
  • the crystalline form-M 2 of cabozantinib free base may be further characterized by the XRPD pattern in FIGURE 14.
  • the crystalline form-M 2 of cabozantinib free base may also be characterized by DSC thermogram in FIGURE 15.
  • the crystalline form-M 2 of cabozantinib free base may also be characterized by the TGA trace as in FIGURE 16.
  • Another aspect of the present invention provides the novel crystalline form-M 3 of cabozantinib free base.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-M3 of cabozantinib free base which includes the following steps: a) providing cabozantinib base in an ester solvent,
  • cabozantinib base may be provided in an ester solvent.
  • the ester solvent may be, for example, methyl acetate, ethyl acetate, propyl acetate, or n-butyl acetate.
  • ethyl acetate was found to be a particularly useful ester solvent.
  • the ester solvent may be substantially removed from the reaction mass, for example by Evaporation, Heating and Distillation, preferably Distillation.
  • an ethereal solvent may be added.
  • Suitable ethereal solvents include, as examples, dimethyl ether, diethyl ether, diisopropyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1, 4-dioxane.
  • diisopropyl ether was found to be a particularly useful ethereal solvent.
  • crystalline form-M3 of cabozantinib free base may be isolated.
  • cabozantinib base may be provided in an ester solvent, for example, ethyl acetate, is provided. Next, the solvent may be distilled out.
  • crystalline form-M3 of cabozantinib free base may be characterized by the XRPD pattern having peaks at about 15.5, 17.7, 19.6, and 21.1 ( ⁇ ) 0.2° 2- theta.
  • the crystalline form-M 3 of cabozantinib free base may be further characterized by the XRPD pattern having peaks at about 4.9, 9.7, 12.0, 15.5, 17.7, 19.6, 21.1, 23.1, 24.1, and 26.6 ( ⁇ ) 0.2° 2-theta
  • the crystalline form-M3 of cabozantinib free base may also be further characterized by the XRPD pattern in FIGURE 17.
  • Another aspect of the present invention provides a process for the preparation of crystalline cabozantinib (S)-malate form N-1 which includes the following steps: a) providing cabozantinib base and (S)-malic acid in a first polar solvent,
  • cabozantinib base and (S)-malic acid may be provided in a first polar solvent.
  • the first polar solvent may be, for example, methanol, ethanol, propanol, butanol, ethyl acetate, acetone, acetonitrile, dichloromethane, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, 1,4-dioxane, water, or mixtures thereof.
  • a mixture of tetrahydrofuran and water was found to be particularly useful for this step.
  • a second solvent may be added to the reaction mass.
  • the second solvent may be a nitrile solvent, for example, acetonitrile.
  • the solution may then be seeded with Form N-1 of cabozantinib (S)-malate, and Form N-1 of cabozantinib (S)-malate may then be isolated.
  • cabozantinib base and (S)- malic acid may be added to a solvent, for example, a mixture of tetrahydrofuran and water.
  • a solvent for example, a mixture of tetrahydrofuran and water.
  • the suspension may then be heated to about 55°C to about 65 °C and a second solvent, for example, acetonitrile, may be added to the reaction mass.
  • a seed of form N-1 of cabozantinib (S)-malate may then be added to the solution which is then cooled to about 20°C to about 35°C.
  • the resulted solid may then be filtered and dried to get the crystalline form N-1 of cabozantinib (S)- malate.
  • the reaction conditions e.g., reaction time or temperature
  • the reaction conditions may be adjusted to achieve appropriate yield without undertaking undue experimentation and without departing from the scope of the present disclosure.
  • the cabozantinib polymorphs and cabozantinib free base polymorphs of the present invention may be included in capsules for oral administration.
  • pharmaceutically acceptable excipients including microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, fumed silica, and stearic acid.
  • the capsule may have a shell which may contain one or more of the following ingredients: black iron oxide, red iron oxide, and titanium dioxide.
  • the cabozantinib polymorphs and cabozantinib free base polymorphs disclosed herein may be included in formulations prescribed for the treatment of medullary thyroid cancer and progressive, metastatic medullary thyroid cancer, in particular.
  • the cabozantinib polymorphs and cabozantinib free base polymorphs disclosed herein may be formulated as a solid dosage form, such as a capsule, containing about 20 mg to about 80 mg per capsule for administration to patients.
  • Example 1 Preparation of cabozantinib (S)-malate crystalline form-Mi
  • Example 3 Preparation of cabozantinib (S)-malate crystalline form-Mi
  • Cabozantinib (S)-malate (3 g) was dissolved in THF (36 ml) and water (3 ml) mixture at 60-65 °C and then cooled to room temperature. The resulting clear solution was added to n-heptane (120 ml) solution at 25-30 °C and stirred at room temperature for 1 -2 hours. The solid obtained was filtered and dried under vacuum at 45 °C for 5 hours. The product obtained was identified as cabozantinib (S)-malate crystalline form-Mi.
  • Example 4 Preparation of cabozantinib (S)-malate crystalline form-M2
  • Example 6 Preparation of cabozantinib (S)-malate crystalline form-M4 Cabozantinib free base (1 g) and (S)-malic acid (0.32 g) were dissolved in a mixture of THF (15 ml) and water (1 ml) at 60-65 °C for 60 minutes and the reaction mass was cooled to room temperature. The resulting clear solution was added to an n-heptane solution (15 ml) at 50-55 °C and maintained under agitation for 120 minutes. The resulting reaction mass was cooled to 25- 30 °C and maintained for 60 minutes The obtained solid was filtered and washed with n-heptane (10 ml). The resulted product was dried under vacuum at 60 °C for 180 minutes. The obtained product was identified as cabozantinib (S)-malate crystalline form-Mi.
  • Cabozantinib (S)-malate 50 mg was dissolved in 1 -methyl-2-pyrrolidone (0.5 ml) at 25-30 °C and maintained at 25-30 °C for 2 days without agitation. Water (5 ml) was added to the clear solution resulting in a suspension. Acetone (3 ml) was added to the suspension and heated to 50 °C to get clear solution. Water (5 ml) was added to the clear solution under agitation and maintained at 25-30 °C for 2 hours without agitation. The solid obtained was filtered and identified as cabozantinib free base crystalline form-Mi.
  • Example 10 Preparation of cabozantinib free base crystalline form-M2
  • Cabozantinib base (12.0 g) was dissolved in a methanol (120 ml) and dichloromethane (120 ml)) mixture at 28-38 °C.
  • Charcoal (10%) was added to the resulting clear solution, and the reaction mass was filtered through celite bed.
  • the obtained clear filtrate was distilled under atmospheric pressure at 40-45 °C. The distillation continued until about 10 volumes (120 ml) of solution along with the solid remained inside.
  • the slurry was cooled to 25-30 °C. Then after the slurry was stirred at 25-30 °C room temperature for 1.0 hours.
  • the product was filtered and dried under vacuum at 50-55 °C for 2 hours.
  • the product obtained was identified as non-solvated crystalline cabozantinib free base form-M2.
  • Example 11 Preparation of cabozantinib free base crystalline form-M3 l-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanecarboxylic acid (2.0 g) was reacted with 4-fluoroaniline hydrochloride (1.08 g) in presence of EDC-HC1 (2.8 g), 1- hydroxybenztriazole (1.98 g), and diisopropylethylamine (5 ml) in N,N-dimethylformamide (20 ml). The reaction was stirred overnight. After overnight stirring, the reaction mass was quenched with water (60 ml).
  • the cabozantinib base was extracted with ethyl acetate (80 ml). Ethyl acetate was distilled out completely and diisopropyl ether (30 ml) was added. The slurry obtained was filtered and dried under vacuum at 60 °C for 2 hours. The product obtained was identified as cabozantinib free base form-M3.
  • Example 12 Process for preparation of cabozantinib form N-l
  • Example 13 Process for preparation of amorphous cabozantinib-(S)-malate 100 mg of cabozantinib (S)-malate obtained by the process in example 3 was kept in a static dryer and heated at 110-120 °C under vacuum for 20-30 min. The resulting solid was identified as amorphous cabozantinib (S)-malate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides novel crystalline forms of cabozantinib (S)-malate, designated as form-M1, M2, M3 and M4 and novel crystalline forms of cabozantinib free base, form-M1, M2 and M3 and methods of their production. The present disclosure also provides processes for the preparation of crystalline cabozantinib (S)-malate form N-1. Formula (I)

Description

NOVEL POLYMORPHS OF CABOZANTINIB (S)-MALATE AND
CABOZANTINIB FREE BASE
CROSS-REFERENCE TO RELATED APPLICATIONS
This application, in its entirety, claims the benefit of earlier Indian provisional patent application No 2561/CHE/2014 filed on May 23, 2014.
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates generally to novel crystalline forms of cabozantinib (S)-malate, designated as form-Mi, M2, M3, and M4 and novel crystalline forms of cabozantinib free base, form-Mi, M2 and M3. The present invention also relates to process for the preparation of crystalline forms of cabozantinib (S)-malate, designated as form-Mi, M2, M3, and M4 and novel crystalline forms of cabozantinib free base, form-Mi, M2 and M3 as well as crystalline cabozantinib (S)-malate form N-l .
BACKGROUND OF THE INVENTION
Cabozantinib (S)-malate, chemically known as N-(4-(6, 7-dimethoxyquinolin-4-yloxy) phenyl)- N'-(4-fluorophenyl) cyclopropane- 1, 1 -dicarboxamide (S)-malate is structurally represented as Formula-I below. Cabozantinib is marketed under the trade name COMETRIQ® by Exelixis, Inc. COMETRIQ® is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Formula-I The chemical structure of cabozantinib is disclosed in U.S. Patent No. 7,579,473, which is hereby incorporated by reference. U.S. Patent No. 8,877,776, which is also hereby incorporated by reference, discloses amorphous forms of cabozantinib L- and D-malate as well as the N-1 and N-2 polymorphs of crystalline cabozantinib L- and D-malate.
The present invention provides novel crystalline forms of cabozantinib (S)-malate and novel crystalline forms of cabozantinib free base.
SUMMARY OF THE I VENTION
One aspect of the present invention provides novel crystalline forms-Mi, M2, M3 and M4 of cabozantinib (S)-malate.
One embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib (S)-malate which includes the steps of:
a) dissolving cabozantinib (S)-malate in a solvent or mixture of solvents, b) adding the above solution of step (a) to non-polar solvent, and
c) isolating the crystalline form-Mi of cabozantinib (S)-malate.
Another embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib (S)-malate which includes the steps of:
a) dissolving cabozantinib base and (S)-malic acid in a solvent or mixture of solvents,
b) adding the above solution of step (a) to non-polar solvent, and
c) isolating the crystalline form-Mi of cabozantinib (S)-malate.
Another embodiment of the present invention a process for the preparation of crystalline form- Mi of cabozantinib (S)-malate which includes the steps of: a) dissolving cabozantinib (S)-malate in a polar solvent,
b) adding an ethereal solvent, and
c) isolating the crystalline form-M2 of cabozantinib (S)-malate.
Another embodiment of the present invention provides a process for the preparation of crystalline form-M3 of cabozantinib (S)-malate which includes the steps of: a) dissolving cabozantinib (S)-malate in a polar solvent,
b) adding water, and
c) isolating the crystalline form-M3 of cabozantinib (S)-malate.
Another embodiment of the present invention provides a process for the preparation of crystalline form-M4 of cabozantinib (S)-malate which includes the steps of: a) dissolving cabozantinib base and (S)-malic acid in a solvent to create a solution, b) adding the solution to a non-polar solvent, and
c) isolating the crystalline form-M4 of cabozantinib (S)-malate.
Another embodiment of the present invention provides a process for the preparation of crystalline form-M4 of cabozantinib (S)-malate which includes the steps of: a) dissolving cabozantinib (S)-malate in an amide solvent,
b) adding a solvent to the reaction mixture, and
c) isolating the crystalline form-M4 of cabozantinib (S)-malate.
Another aspect of the present invention provides novel crystalline forms-Mi, M2 and M3 of cabozantinib free base.
One embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib free base which includes the steps of: a) dissolving cabozantinib (S)-malate in a solvent to create a solution,
b) adding water to the solution,
c) adding ketone solvent, and
d) isolating the crystalline form-Mi of cabozantinib free base.
Another embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib free base which includes the steps of: a) dissolving cabozantinib (S)-malate in a solvent to create a solution,
b) adding water to the solution, and
c) isolating the crystalline form-Mi of cabozantinib free base. Another embodiment of the present invention provides a process for the preparation of crystalline form-M2 of cabozantinib free base which includes the steps of: a) dissolving cabozantinib in a solvent,
b) partially removing the solvent, and
c) isolating the crystalline form-M2 of cabozantinib free base
Another embodiment of the present invention provides a process for the preparation of crystalline form-M3 of cabozantinib free base which includes the steps of: a) providing cabozantinib base in an ester solvent,
b) removing the ester solvent,
c) adding an ethereal solvent, and
d) isolating the crystalline form-M3 of cabozantinib free base.
Yet another aspect of the present invention provides a process for the preparation of crystalline cabozantinib (S)-malate form N-l which includes the steps of: a) providing cabozantinib base and (S)-malic acid in a first polar solvent, b) adding second solvent,
c) seeding with form N-l of cabozantinib (S)-malate, and
d) isolating the cabozantinib (S)-malate form N-l .
BRIEF DESCRIPTION OF THE DRAWINGS
Further objects of the present invention together with additional features contributing thereto and advantages accruing there from will be apparent from the following description of preferred embodiments of the invention which are shown in the accompanying drawing figures wherein:
FIGURE 1 is a powder X-ray diffraction pattern of crystalline cabozantinib (S)-malate form-Mi; FIGURE 2 is a DSC thermogram of crystalline cabozantinib (S)-malate form-Mi;
FIGURE 3 is a TGA trace of crystalline cabozantinib (S)-malate form-Mi;
FIGURE 4 is a powder X-ray diffraction pattern of crystalline cabozantinib (S)-malate form-M2; FIGURE 5 is a DSC thermogram of crystalline cabozantinib (S)-malate form-M2;
FIGURE 6 is a TGA trace of crystalline cabozantinib (S)-malate form-M2; FIGURE 7 is a powder X-ray diffraction pattern of crystalline cabozantinib (S)-malate form-M3; FIGURE 8 is a powder X-ray diffraction pattern of crystalline cabozantinib (S)-malate form-Mt; FIGURE 9 is a DSC thermogram of crystalline cabozantinib (S)-malate form-Mt;
FIGURE 10 is a TGA trace of crystalline cabozantinib (S)-malate form-Mt;
FIGURE 11 is a powder X-ray diffraction pattern of crystalline cabozantinib free base form-Mi; FIGURE 12 is a DSC thermogram of crystalline cabozantinib free base form-Mi;
FIGURE 13 is a TGA trace of crystalline cabozantinib free base form-Mi;
FIGURE 14 is a powder X-ray diffraction pattern of crystalline cabozantinib free base form-M2; FIGURE 15 is a DSC thermogram of crystalline cabozantinib free base form-M2;
FIGURE 16 is a TGA trace of crystalline cabozantinib free base form-M2; and
FIGURE 17 is a powder X-ray diffraction pattern of crystalline cabozantinib free base form-M3.
DETAILED DESCRIPTION OF THE INVENTION
It is to be understood that the description of the present invention has been simplified to illustrate elements that are relevant for a clear understanding of the invention, while eliminating, for purposes of clarity, other elements that may be well known.
The present disclosure provides novel crystalline forms-Mi, M2, M3 and M4 of cabozantinib (S)- malate and crystalline forms-Mi, M2 and M3 of cabozantinib free base. The present disclosure also provides processed for the preparation of crystalline forms-Mi, M2, M3 and M4 of cabozantinib (S)-malate and crystalline forms-Mi, M2 and M3 of cabozantinib free base as well as crystalline cabozantinib (S)-malate form N-l.
One aspect of the present invention provides crystalline form-Mi of cabozantinib (S)-malate.
One embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib (S)-malate in a solvent to create a solution,
b) adding the above solution of step (a) to a non-polar solvent, and
c) isolating the crystalline form-Mi of cabozantinib (S)-malate. According to the present invention, cabozantinib (S)-malate may be dissolved in a solvent to create a solution. Within the context of the present invention, the solvent used for dissolving cabozantinib (S)-malate may be, for example, ethereal, alcoholic, water, or mixtures thereof. Examples of suitable ethereal solvents include dimethyl ether, diethyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1,4-dioxane. Suitable alcohols include, for example, methanol, ethanol, propanol, and butanol. In certain embodiments, a mixture of tetrahydrofuran and water was found to be a particularly useful solvent for dissolving cabozantinib (S)-malate.
Next, the solution of cabozantinib (S)-malate may be added to a non-polar solvent. The non- polar solvent may be, for example, a Ci-Cio alkane or a mixture of Ci-Cio alkanes. In certain embodiments, n-heptane was found to be a particularly useful non-polar solvent. The obtained solid may then be isolated to get a crystalline form-Mi of cabozantinib (S)-malate.
In particularly useful embodiments of the present invention, cabozantinib (S)-malate may be dissolved in tetrahydrofuran and water at a temperature of about 55°C to about 70°C. The reaction temperature may then be cooled to room temperature. The resulting clear solution may then be added to a non-polar solvent such as n-heptane. The obtained solid may be filtered and dried to get the crystalline form-Mi of cabozantinib (S)-malate.
Another embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib (S)-malate which includes the following steps:
a) dissolving cabozantinib base and (S)-malic acid in a solvent to create a solution, b) adding the above solution of step (a) to non-polar solvent, and
c) isolating the crystalline form-Mi of cabozantinib (S)-malate.
According to the present invention, cabozantinib base and (S)-malic acid may be dissolved in a solvent. Within the context of the present invention, the solvent may be, for example, an ethereal solvent, an alcoholic solvent, water, or a mixture thereof. Examples of suitable ethereal solvents include dimethyl ether, diethyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1,4-dioxane. Examples of suitable alcohols include methanol, ethanol, propanol, and butanol. In some embodiments of the present invention, a mixture of tetrahydrofuran and water was found to be particularly useful. In some embodiments, tetrahydrofuran and water in a ratio of 12: 1 was found to be particularly useful. Next, the solution of cabozantinib (S)-malate may be added to a non-polar solvent. The non- polar solvent may be, for example, a Ci-Cio alkane or a mixture of Ci-Cio alkanes. In certain embodiments, n-heptane was found to be a particularly useful non-polar solvent. The obtained solid may then be isolated to get a crystalline form-Mi of cabozantinib (S)-malate. In particularly useful embodiments of the present invention, cabozantinib base and (S)-malic acid may be dissolved in a mixture of solvents such as tetrahydrofuran and water at a temperature between about 55°C to about 70°C. The temperature of the solution may then be cooled to room temperature. The resulting clear solution may then be added to non-polar solvent, for example, n-heptane, at about 20°C to about 35°C. The obtained solid may then be filtered and dried under vacuum to get the crystalline form-Mi of cabozantinib (S)-malate.
The crystalline polymorph forms of compounds disclosed in the present invention may be characterized by X-ray powder diffraction ("XRPD") pattern. Thus, the XRPD patterns of the polymorphs of the present disclosure were measured.
The XRPD patterns were measured on BRUKER D-8 Discover powder diffractometer equipped with goniometer of Θ/2Θ configuration and Lynx Eye detector. The Cu-anode X-ray tube was operated at 40kV and 30mA. The experiments were conducted over the 2Θ range of 2.0°-50.0°, 0.030° step size and 0.4 seconds step time.
According to the present invention, crystalline form-Mi of cabozantinib (S)-malate may be characterized by an XRPD pattern having characteristic peak at about 13.2 (±) 0.2° 2-theta. Within the context of the present invention, the crystalline form-Mi of cabozantinib (S)-malate may be further characterized by the XRPD pattern in FIGURE 1.
The crystalline polymorph forms of compounds disclosed in the present invention may also be characterized by differential scanning calorimetry (DSC). Thus, DSC thermograms of the polymorphs of the disclosure were measured. The DSC measurements were carried out on TA Q1000 of TA Instruments. The experiments were performed at a heating rate of 20.0 °C/min over a temperature range of 30°C-330°C purging with nitrogen at a flow rate of 50 ml/min. Standard aluminum crucibles covered by lids with pin holes were used.
According to the present invention, the crystalline form-Mi of cabozantinib (S)-malate may be characterized by the DSC thermogram in FIGURE 2. The crystalline polymorph forms of compounds disclosed in the present invention may also be characterized by thermogravimetric analysis (TGA). Thus, the TGA/DTA traces of the polymorphs of the disclosure were measured.
TGA/DTA was recorded using the instrument TA Q5000 IR of TA Instruments. The experiments were performed at a heating rate of 10.0 °C/min over a temperature range of 30°C- 350°C purging with nitrogen at a flow rate of 25 ml/min.
According to the present invention, the crystalline form-Mi of cabozantinib (S)-malate may be characterized by the TGA trace in FIGURE 3.
Another aspect of the present invention provides crystalline form-M2 of cabozantinib (S)-malate.
One embodiment of the present invention provides a process for the preparation of crystalline form-M2 of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib (S)-malate in a polar solvent to create a solution,
b) adding an ethereal solvent to the solution, and
c) isolating the crystalline form-M2 of cabozantinib (S)-malate.
According to the present invention, cabozantinib (S)-malate may be dissolved in a polar solvent. Within the context of the present invention, the polar solvent may be, for example, formic acid, acetic acid, or propionic acid. In some embodiments of the present invention, propionic acid is a particularly useful solvent.
Next, an ethereal solvent may be added to the reaction mass. Within the context of the present invention, the ethereal solvent may be, for example, dimethyl ether, diethyl ether, ethyl methyl ether, methyl-t-butyl ether, tetrahydrofuran, or 1,4-dioxane. In some embodiments, methyl-t- butyl ether was found to be a particularly useful solvent. Crystalline form-M2 of cabozantinib (S)-malate may then be isolated.
In particularly useful embodiments of the present invention, cabozantinib (S)-malate may be dissolved in a polar solvent such as propionic acid at temperature about 45°C to about 55°C and then cooled to about 20°C to about 35°C. An ethereal solvent such as methyl-t-butyl ether may then be added to the reaction mixture. The obtained solid may then be filtered and dried to get the crystalline form-M2 of cabozantinib (S)-malate.
According to the present invention, crystalline form-M2 of cabozantinib (S)-malate may be characterized by the XRPD pattern having characteristic peaks at 8.5, 12.5, 20.2, 23.1, and 26.1 (±) 0.2° 2-theta.
Within the context of the present invention, crystalline form-M2 of cabozantinib (S)-malate may be further characterized by XRPD pattern having characteristic peaks at 8.5, 12.5, 14.3, 20.2, 22.2, 23.1, 26.1, 26.6, and 26.9 (±) 0.2° 2-theta.
Within the context of the present invention, the crystalline form-M2 of cabozantinib (S)-malate may be further characterized by the XRPD pattern in FIGURE 4.
The crystalline form-M2 of cabozantinib (S)-malate may also be characterized by the DSC thermogram in FIGURE 5.
The crystalline form-M2 of cabozantinib (S)-malate may additionally be characterized by the TGA trace in FIGURE 6. Another aspect of the present invention provides crystalline form-M3 of cabozantinib (S)-malate.
One embodiment of the present invention provides a process for the preparation of crystalline form-M3 of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib (S)-malate in a polar solvent to create a solution,
b) adding water to the solution, and
c) isolating the crystalline form-M3 of cabozantinib (S)-malate. According to the present invention, cabozantinib (S)-malate may be dissolved in a polar solvent. Within the context of the present invention, the polar solvent may be, for example, formic acid, acetic acid, or propionic acid. In certain embodiments, acetic acid was found to be a particularly useful polar solvent. Next, water is added to the reaction mass and crystalline form-M3 of cabozantinib (S)-malate may then be isolated.
In particularly useful embodiments of the present invention, cabozantinib (S)-malate may be dissolved in a polar solvent, such as acetic acid, at a temperature between about 55°C and about 65°C. The resulting clear solution may be cooled to about -5°C to about 10°C, and water may be added to the reaction mass. The obtained solid may then be filtered and washed with water to get the crystalline form-M3 of cabozantinib (S)-malate.
According to the present invention, crystalline form-M3 of cabozantinib (S)-malate may be characterized by the XRPD pattern having characteristic peaks, 11.9, 12.6, and 18.1 (±) 0.2° 2- theta.
Within the context of the present invention, crystalline form-M3 of cabozantinib (S)-malate may be further characterized by the XRPD pattern having characteristic peaks at 6.3, 9.1, 11.9, 12.6, 13.6, 15.1, 16.9, 18.1, 19.1, 21.2, 23.7, 25.8, 27.5, 30.1 , and 31.0 (±) 0.2° 2-theta.
The crystalline form- M3 of cabozantinib (S)-malate may also be further characterized by the powder X-ray diffractogram in FIGURE 7.
Another aspect of the present invention provides the crystalline form-Mi of cabozantinib (S)- malate.
One embodiment of the present invention provides a process for the preparation of crystalline form-M4 of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib base and (S)-malic acid in a solvent to create a solution, b) adding the above solution of step (a) to a non-polar solvent,
c) isolating the crystalline form-Mi of cabozantinib (S)-malate.
According to the present invention, cabozantinib base and (S)-malic acid may be dissolved in a solvent. Within the context of the present invention, the solvent may be, for example, an ethereal solvent, an alcoholic solvent, water, or a mixture thereof. Examples of suitable ethereal solvents include dimethyl ether, diethyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1,4-dioxane. Suitable alcohols include, for example, methanol, ethanol, propanol, and butanol. In some embodiments of the present invention, a mixture of tetrahydrofuran and water was found to be particularly useful. In some embodiments, a ratio of 15: 1 tetrahydrofuran to water was found to be particularly useful.
Next, the solution of cabozantinib (S)-malate may be added to a non-polar solvent. The non- polar solvent may be, for example, a Ci-Cio alkane or a mixture of Ci-Cio alkanes. In certain embodiments, n-heptane was found to be a particularly useful non-polar solvent. The obtained solid may then be isolated to get a crystalline form-Mi of cabozantinib (S)-malate.
In particularly useful embodiments of the present invention, cabozantinib base and (S)-malic acid may be dissolved in a mixture of solvents, such as tetrahydrofuran and water, at a temperature between about 55°C and about 70°C. The reaction temperature may then be cooled to room temperature. The resulted clear solution may then be added to a non-polar solvent, for example, n-heptane, at about 45°C to about 60°C. The resulted reaction mass may be cooled to about 20°C to about 35°C. The obtained solid is filtered and dried under vacuum to get the crystalline form-M4 of cabozantinib (S)-malate.
Another embodiment of the present invention provides a process for the preparation of crystalline form-M4 of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib (S)-malate in an amide solvent to create a solution, b) adding a solvent to the solution, and
c) isolating the crystalline form-Mi of cabozantinib (S)-malate.
According to the present invention, cabozantinib (S)-malate may be dissolved in an amide solvent to create a solution. Within the context of the present invention, the amide solvent may be, for example, N,N-dimethylacetamide, Ν,Ν-dimethylformamide, or N-methylpyrrolidone. In some embodiments of the present invention, Ν,Ν-dimethylacetamide was found to be a particularly useful solvent. Next, a solvent may be added to the solution. Within the context of the present invention, the solvent may be, for example, an ethereal solvent, an alcoholic solvent, water, or mixtures thereof. Examples of suitable ethereal solvents include dimethyl ether, diethyl ether, ethyl methyl ether, methyl-t-butyl ether, tetrahydrofuran, and 1,4-dioxane. Examples of suitable alcohol solvents include methanol, ethanol, propanol, and butanol. In some embodiments, a mixture of methyl-t- butyl ether and ethanol was found to be particularly useful. Next, the solid may be isolated to get a crystalline form-Mi of cabozantinib (S)-malate.
In particularly useful embodiments of the present invention, cabozantinib (S)-malate may be dissolved in an amide solvent such as Ν,Ν-dimethylacetamide at a temperature between about 45°C and about 55°C to create a clear solution. Methyl-t-butyl ether and ethanol may then be added to the clear solution at room temperature. The obtained solid may then be filtered and dried to get the crystalline form-Mi of cabozantinib (S)-malate.
According to the present invention, crystalline form-M4 of cabozantinib (S)-malate may be characterized by the XRPD pattern having characteristic peaks at about 13.3, 15.0, 22.8, and 25.8 (±) 0.2° 2-theta.
The crystalline form-Mt of cabozantinib (S)-malate may be further characterized by the XRPD pattern having characteristic peaks at 9.3, 13.3, 15.0, 19.5, 20.9, 22.8, 25.8, and 26.9 (±) 0.2° 2- theta.
Within the context of the present invention, the crystalline form-Mi of cabozantinib (S)-malate may also be characterized by the PXRD pattern in FIGURE 8.
The crystalline form-Mi of cabozantinib (S)-malate may be additionally characterized by the DSC thermogram in FIGURE 9.
According to the present invention, the crystalline form-Mi of cabozantinib (S)-malate may be characterized by the TGA trace in FIGURE 10. Another aspect of the present invention provides the novel crystalline form-Mi of cabozantinib free base. One embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib free base which includes the following steps: a) dissolving cabozantinib (S)-malate in a solvent to create a solution,
b) adding water to the solution,
c) adding ketone solvent, and
d) isolating crystalline form-Mi of cabozantinib free base.
According to the present invention, cabozantinib (S)-malate may be dissolved in a solvent to create a solution. Within the context of the present invention, the solvent may be, for example, Ν,Ν-dimethylacetamide, N,N-dimethylformamide, N-methyl-2-pyrrolidone, dimethyl sulfoxide, acetonitrile, dichloromethane, tetrahydrofuran, or ethyl acetate. In some embodiments of the present invention, N-methyl-2-pyrrolidone was found to be a particularly useful solvent.
Next, water may be added to the reaction mass followed by a ketone solvent. Within the context of the present invention, the ketone solvent may be, for example, acetone, methyl ethyl ketone, or methyl isobutyl ketone. In some embodiments of the present invention, acetone was found to be a particularly useful solvent. The crystalline form-Mi of cabozantinib free base may then be isolated.
In particularly useful embodiments of the present invention, cabozantinib (S)-malate may be dissolved in a solvent, such as N-methyl-2-pyrrolidone, at a temperature between about 20°C and about 35°C. Water may then be added to the clear solution. Next, a ketone solvent, for example, acetone, may be added, and the reaction mixture heated to about 45°C to about 55°C. Water may then be added while the reaction mixture is maintained at a temperature between about 20°C and about 35°C. The obtained solid may then be filtered to get the crystalline form-Mi of cabozantinib free base.
Another embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib free base, which includes the following steps: a) dissolving cabozantinib (S)-malate in a solvent to form a solution,
b) adding water to the solution, and
c) isolating the crystalline form-Mi of cabozantinib. According to the present invention, cabozantinib (S)-malate may be dissolved in a solvent to create a solution. The solvent may be, for example, Ν,Ν-dimethylacetamide, N,N- dimethylformamide, N-methyl-2-pyrrolidone, dimethyl sulfoxide, acetonitrile, dichloromethane, tetrahydrofuran, or ethyl acetate. In some embodiments of the present invention, dimethyl sulfoxide was found to be a particularly useful solvent. Next, water may be added to the reaction mass and the crystalline form-Mi of cabozantinib may be isolated. In particularly useful embodiments of the present invention, cabozantinib (S)-malate may be dissolved in a solvent, for example, in dimethyl sulfoxide, at a temperature of about 20°C to about 35°C. Water may then be added and the obtained solid is filtered to get the crystalline form-Mi of cabozantinib free base.
According to the present invention, crystalline form-Mi of cabozantinib free base may be characterized by the XRPD pattern having peaks at about 11.8 (±) 0.2° 2-theta.
Within the context of the present invention, crystalline form-Mi of cabozantinib free base may be further characterized by the XRPD pattern having peaks at about 11.8, 12.8, 14.3, 17.8, and 22.7 (±) 0.2° 2-theta
The crystalline form-Mi of cabozantinib free base may be further characterized by the XRPD pattern as depicted in FIGURE 11.
According to the present invention, the crystalline form-Mi of cabozantinib free base may be characterized by the DSC thermogram in FIGURE 12.
According to the present invention, the crystalline form-Mi of cabozantinib free base may also be characterized by the TGA trace in FIGURE 13.
Another aspect of the present invention provides the novel crystalline form-M2 of cabozantinib free base.
One embodiment of the present invention provides a process for the preparation of crystalline form-M2 of cabozantinib free base which includes the following steps: a) dissolving cabozantinib in a solvent,
b) partially removing the solvent, and c) isolating the crystalline form-M2 of cabozantinib free base.
According to the present invention, cabozantinib may be dissolved in a solvent. Within the context of the present invention, the solvent may be, for example, halogenated, alcoholic, or a mixture thereof. Suitable halogenated solvents include, for example, dichloromethane and dichloroethane. Suitable alcohols include, for example, methanol, ethanol, propanol, and butanol. In some embodiments of the present invention, a mixture of methanol and dichloromethane was found to be particularly useful. Next, some of the solvent is removed, for example by Evaporation, Heating and Distillation, preferably Distillation.
The crystalline form-M2 of cabozantinib free base may then be isolated. In particularly useful embodiments of the present invention, cabozantinib may be dissolved in a mixture of solvents, for example a mixture methanol and dichloromethane, at about 25°C to about 45°C. The resulting clear solution may then be partially distilled out under atmospheric pressure to obtain a slurry. The slurry is then cooled to a temperature between about 20 °C and about 35 °C and filtered to get the crystalline form-M2 of cabozantinib free base. According to the present invention, crystalline form-M2 of cabozantinib free base may be characterized by the XRPD pattern having peaks at about 12.6, 14.1, 18.5, 22.1, 23.2, 24.1, and 29.0 (±) 0.2° 2-theta.
Within the context of the present invention, the crystalline form-M2 of cabozantinib free base may further characterized by the XRPD pattern having peaks at about 7.8, 11.1, 11.5, 12.6, 14.1, 15.4, 17.2, 18.5, 19.2, 21.1, 22.1, 23.2, 24.1, and 29.0 (±) 0.2° 2-theta
The crystalline form-M2 of cabozantinib free base may be further characterized by the XRPD pattern in FIGURE 14.
The crystalline form-M2 of cabozantinib free base may also be characterized by DSC thermogram in FIGURE 15. The crystalline form-M2 of cabozantinib free base may also be characterized by the TGA trace as in FIGURE 16. Another aspect of the present invention provides the novel crystalline form-M3 of cabozantinib free base.
One embodiment of the present invention provides a process for the preparation of crystalline form-M3 of cabozantinib free base which includes the following steps: a) providing cabozantinib base in an ester solvent,
b) removing the ester solvent,
c) adding an ethereal solvent, and
d) isolating the crystalline form-M3 of cabozantinib free base.
According to the present invention, cabozantinib base may be provided in an ester solvent. Within the context of the present invention, the ester solvent may be, for example, methyl acetate, ethyl acetate, propyl acetate, or n-butyl acetate. In some embodiments of the present invention, ethyl acetate was found to be a particularly useful ester solvent. Next, the ester solvent may be substantially removed from the reaction mass, for example by Evaporation, Heating and Distillation, preferably Distillation. Next, an ethereal solvent may be added. Suitable ethereal solvents include, as examples, dimethyl ether, diethyl ether, diisopropyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1, 4-dioxane. In some embodiments of the present invention, diisopropyl ether was found to be a particularly useful ethereal solvent. Next, crystalline form-M3 of cabozantinib free base may be isolated. In particularly useful embodiments of the present invention, cabozantinib base may be provided in an ester solvent, for example, ethyl acetate, is provided. Next, the solvent may be distilled out. Next, an ethereal solvent, for example, diisopropyl ether, may be added to create a slurry. The obtained slurry may be filtered and dried under vacuum to get the crystalline form-M3 of cabozantinib free base. According to the present invention, crystalline form-M3 of cabozantinib free base may be characterized by the XRPD pattern having peaks at about 15.5, 17.7, 19.6, and 21.1 (±) 0.2° 2- theta. Within the context of the present invention, the crystalline form-M3 of cabozantinib free base may be further characterized by the XRPD pattern having peaks at about 4.9, 9.7, 12.0, 15.5, 17.7, 19.6, 21.1, 23.1, 24.1, and 26.6 (±) 0.2° 2-theta
The crystalline form-M3 of cabozantinib free base may also be further characterized by the XRPD pattern in FIGURE 17.
Another aspect of the present invention provides a process for the preparation of crystalline cabozantinib (S)-malate form N-1 which includes the following steps: a) providing cabozantinib base and (S)-malic acid in a first polar solvent,
b) adding a second solvent to the reaction mass,
c) seeding form N-1 of cabozantinib (S)-malate, and
d) isolating the cabozantinib (S)-malate form N-1.
According to the present invention, cabozantinib base and (S)-malic acid may be provided in a first polar solvent. Within the context of the present invention, the first polar solvent may be, for example, methanol, ethanol, propanol, butanol, ethyl acetate, acetone, acetonitrile, dichloromethane, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, 1,4-dioxane, water, or mixtures thereof. In some embodiments of the present invention, a mixture of tetrahydrofuran and water was found to be particularly useful for this step.
Next, a second solvent may be added to the reaction mass. Within the context of the present invention, the second solvent may be a nitrile solvent, for example, acetonitrile. The solution may then be seeded with Form N-1 of cabozantinib (S)-malate, and Form N-1 of cabozantinib (S)-malate may then be isolated.
In some particularly useful embodiments of the present invention, cabozantinib base and (S)- malic acid may be added to a solvent, for example, a mixture of tetrahydrofuran and water. The suspension may then be heated to about 55°C to about 65 °C and a second solvent, for example, acetonitrile, may be added to the reaction mass. A seed of form N-1 of cabozantinib (S)-malate may then be added to the solution which is then cooled to about 20°C to about 35°C. The resulted solid may then be filtered and dried to get the crystalline form N-1 of cabozantinib (S)- malate. With all of the reactions disclosed above, one of skill in the art will recognize that the reaction conditions (e.g., reaction time or temperature) may be adjusted to achieve appropriate yield without undertaking undue experimentation and without departing from the scope of the present disclosure. In some embodiments, the cabozantinib polymorphs and cabozantinib free base polymorphs of the present invention may be included in capsules for oral administration. One of skill in the art will recognize a wide variety of pharmaceutically acceptable excipients that may be included in such a capsule formulation, including microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, fumed silica, and stearic acid. The capsule may have a shell which may contain one or more of the following ingredients: black iron oxide, red iron oxide, and titanium dioxide.
The cabozantinib polymorphs and cabozantinib free base polymorphs disclosed herein may be included in formulations prescribed for the treatment of medullary thyroid cancer and progressive, metastatic medullary thyroid cancer, in particular. The cabozantinib polymorphs and cabozantinib free base polymorphs disclosed herein may be formulated as a solid dosage form, such as a capsule, containing about 20 mg to about 80 mg per capsule for administration to patients.
In view of the above description and the examples below, one of ordinary skill in the art will be able to practice the invention as claimed without undue experimentation. The foregoing will be better understood with reference to the following examples that detail certain procedures for the preparation of molecules, compositions and formulations according to the present invention. All references made to these examples are for the purposes of illustration. The following examples should not be considered exhaustive, but merely illustrative of only a few of the many aspects and embodiments contemplated by the present disclosure.
Examples: Example 1: Preparation of cabozantinib (S)-malate crystalline form-Mi
Cabozantinib base (2 g) and (S)-malic acid (0.64 g) were dissolved in a mixture of THF (24 ml) and water (2 ml) at 60-65 °C and the reaction mass was cooled to room temperature. The resulting clear solution was added to n-heptane (80ml) at 25-30 °C and stirred at room temperature for 2 hours. The solid obtained was filtered and dried under vacuum at 45 °C for 5 hours. The product obtained was identified as cabozantinib (S)-malate crystalline form-Mi.
Example 2: Preparation of cabozantinib (S)-malate crystalline form-Mi
Cabozantinib (S)-malate (l .Og) was dissolved in THF (6 ml) and water (0.2 ml) mixture at 60- 65°C and then cooled to room temperature. The resulting clear solution was added to n-heptane (30 ml) solution at 25-30 °C and maintained under agitation at room temperature for 2 hours. The solid obtained was filtered and dried under vacuum at 45 °C for 5 hours. The product obtained was identified as cabozantinib (S)-malate crystalline form-Mi.
Example 3: Preparation of cabozantinib (S)-malate crystalline form-Mi Cabozantinib (S)-malate (3 g) was dissolved in THF (36 ml) and water (3 ml) mixture at 60-65 °C and then cooled to room temperature. The resulting clear solution was added to n-heptane (120 ml) solution at 25-30 °C and stirred at room temperature for 1 -2 hours. The solid obtained was filtered and dried under vacuum at 45 °C for 5 hours. The product obtained was identified as cabozantinib (S)-malate crystalline form-Mi. Example 4: Preparation of cabozantinib (S)-malate crystalline form-M2
Cabozantinib (S)-malate (0.5 g) was dissolved in propionic acid (1.5 ml) at 50 °C and then cooled to 25-30 °C. The resulting clear solution was kept at room temperature for overnight without agitation, methyl-t-butyl ether (15 ml) was added, and the solution was stirred for 60 min. The obtained solid was filtered and dried under vacuum at 70 °C for 10 hours. The product obtained was identified as cabozantinib (S)-malate crystalline form-M2.
Example 5: Preparation of cabozantinib (S)-malate crystalline form-M3
Cabozantinib (S)-malate (100 mg) was dissolved in acetic acid (0.2 ml) at 60 °C. The resulting clear solution was kept at room temperature for 15 hours, cooled to 0-5 °C, then water (5 ml) was added and stirred for 10 min. The solid obtained was filtered and washed with water (1 ml). The product obtained was identified as cabozantinib (S)-malate crystalline form-M3.
Example 6: Preparation of cabozantinib (S)-malate crystalline form-M4 Cabozantinib free base (1 g) and (S)-malic acid (0.32 g) were dissolved in a mixture of THF (15 ml) and water (1 ml) at 60-65 °C for 60 minutes and the reaction mass was cooled to room temperature. The resulting clear solution was added to an n-heptane solution (15 ml) at 50-55 °C and maintained under agitation for 120 minutes. The resulting reaction mass was cooled to 25- 30 °C and maintained for 60 minutes The obtained solid was filtered and washed with n-heptane (10 ml). The resulted product was dried under vacuum at 60 °C for 180 minutes. The obtained product was identified as cabozantinib (S)-malate crystalline form-Mi.
Example 7: Preparation of cabozantinib (S)-malate crystalline form-M4
Cabozantinib (S)-malate (50 mg) was dissolved in N,N-dimethylacetamide (0.5 ml) at 50 °C and the resulting clear solution was kept at room temperature for 2 days without agitation. Methyl-t- butyl ether (8 ml) and ethanol (0.5 ml) were then added and the solution was kept at room temperature for 2 days. To the resulting layer, ethanol (5 ml) was added and kept at room temperature for 7 days without agitation. The solid obtained after solvent evaporation was identified as cabozantinib (S)-malate crystalline form-M4. Example 8: Preparation of cabozantinib free base crystalline form-Mi
Cabozantinib (S)-malate (50 mg) was dissolved in 1 -methyl-2-pyrrolidone (0.5 ml) at 25-30 °C and maintained at 25-30 °C for 2 days without agitation. Water (5 ml) was added to the clear solution resulting in a suspension. Acetone (3 ml) was added to the suspension and heated to 50 °C to get clear solution. Water (5 ml) was added to the clear solution under agitation and maintained at 25-30 °C for 2 hours without agitation. The solid obtained was filtered and identified as cabozantinib free base crystalline form-Mi.
Example 9: Preparation of cabozantinib free base crystalline form-Mi
Cabozantinib (S)-malate (50 mg) was dissolved in DMSO (0.5 ml) at 25-30 °C and maintained at 25-30 °C for 2 days without agitation. Water (5 ml) was then added under agitation and maintained at 25-30 °C for 24 hours. The obtained solid was filtered and identified as cabozantinib free base crystalline form-Mi.
Example 10: Preparation of cabozantinib free base crystalline form-M2 Cabozantinib base (12.0 g) was dissolved in a methanol (120 ml) and dichloromethane (120 ml)) mixture at 28-38 °C. Charcoal (10%) was added to the resulting clear solution, and the reaction mass was filtered through celite bed. The obtained clear filtrate was distilled under atmospheric pressure at 40-45 °C. The distillation continued until about 10 volumes (120 ml) of solution along with the solid remained inside. The slurry was cooled to 25-30 °C. Then after the slurry was stirred at 25-30 °C room temperature for 1.0 hours. The product was filtered and dried under vacuum at 50-55 °C for 2 hours. The product obtained was identified as non-solvated crystalline cabozantinib free base form-M2.
Example 11: Preparation of cabozantinib free base crystalline form-M3 l-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanecarboxylic acid (2.0 g) was reacted with 4-fluoroaniline hydrochloride (1.08 g) in presence of EDC-HC1 (2.8 g), 1- hydroxybenztriazole (1.98 g), and diisopropylethylamine (5 ml) in N,N-dimethylformamide (20 ml). The reaction was stirred overnight. After overnight stirring, the reaction mass was quenched with water (60 ml). The cabozantinib base was extracted with ethyl acetate (80 ml). Ethyl acetate was distilled out completely and diisopropyl ether (30 ml) was added. The slurry obtained was filtered and dried under vacuum at 60 °C for 2 hours. The product obtained was identified as cabozantinib free base form-M3.
Example 12: Process for preparation of cabozantinib form N-l
1.5 g of cabozantinib base and 0.48 g of (S)-malic acid were added in a mixture of THF (18.0 ml) and water (1.5 ml) at 25-30 °C. The reaction mass was heated at 60 °C. The clear solution was maintained at 60 °C for 1 hour. The reaction mass was filtered through filter paper followed by 0.45 micron paper. The clear filtrate was heated again to 60 °C at which point acetonitrile was added over a period of 60 minutes. After acetonitrile was added, a 50 mg seed of form N-l of cabozantinib (S)-malate was added. The reaction suspension was maintained at 60 °C for 4 h. After 4 hours of heating, the reaction mass was cooled to 25-30 °C and stirred for 30 minutes. The product was filtered and washed with 18 ml of acetonitrile. The product was vacuum dried for 30 minutes followed by drying under vacuum at 60-60 °C for 3 hours. The cabozantinib (S)- malate was identified as form N-l .
Example 13: Process for preparation of amorphous cabozantinib-(S)-malate 100 mg of cabozantinib (S)-malate obtained by the process in example 3 was kept in a static dryer and heated at 110-120 °C under vacuum for 20-30 min. The resulting solid was identified as amorphous cabozantinib (S)-malate.

Claims

CLAIMS We claim:
1. A crystalline polymorph form-Mi of cabozantinib (S)-malate.
2. The compound of claim 1, which has an X-ray powder diffraction pattern with a significant peak at about a 2Θ value of 13.2 (±) 0.2°.
3. A crystalline polymorph form-M2 of cabozantinib (S)-malate.
4. The compound of claim 3, which has an X-ray powder diffraction pattern with significant peaks at about 2Θ values of 8.5, 12.5, 20.2, 23.1, and 26.1 (±) 0.2°.
5. A crystalline polymorph form-M3 of cabozantinib (S)-malate.
6. The compound of claim 5, which has an X-ray powder diffraction pattern with significant peaks at about 2Θ values of 11.9, 12.6, and 18.1 (±) 0.2°.
7. Crystalline polymorph form-Mi of cabozantinib (S)-malate.
8. The compound of claim 7, which has an X-ray powder diffraction pattern with significant peaks at about 2Θ values of 13.3, 15.0, 22.8, and 25.8 (±) 0.2°.
9. A process for the preparation of crystalline form-Mi of cabozantinib (S)-malate comprising the steps of:
a) dissolving cabozantinib base and (S)-malic acid in a solvent to create a solution; b) adding the solution to a non-polar solvent; and
c) isolating crystalline form-Mi of cabozantinib (S)-malate.
10. The process according to claim 9, wherein the solvent is selected from an ethereal solvent, an alcoholic solvent, water, or mixtures thereof.
11. The process according to claim 10, wherein the ethereal solvent is selected from the group consisting of dimethyl ether, diethyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
12. The process according to claim 10 wherein the alcoholic solvent is selected from the group consisting of methanol, ethanol, propanol, and butanol.
13. The process according to claim 10, wherein the solvent is a mixture of tetrahydrofuran and water.
14. The process according to claim 13, wherein the mixture of tetrahydrofuran and water are exist in a ratio of 15 : 1.
15. The process according to claim 9, wherein the non-polar solvent is selected from the group consisting of Ci-Cio alkanes or a mixture of Ci-Cio alkanes.
16. The process according to claim 15, wherein non-polar solvent is n-heptane.
17. A process for the preparation of crystalline form-Mi of cabozantinib (S)-malate comprising the steps of:
a) dissolving cabozantinib (S)-malate in an amide solvent to create a reaction mixture;
b) adding a solvent to the reaction mixture; and
c) isolating the crystalline form-Mi of cabozantinib (S)-malate.
18. The process according to claim 17, wherein the amide solvent is selected from the group consisting of N, N-dimethylacetamide, N, N-dimethylformamide, and N- methylpyrrolidone.
19. The process according to claim 18 where the amid solvent is N, N-dimethylacetamide.
20. The process according to claim 17, wherein the solvent selected from the group consisting of an ethereal solvent, an alcoholic solvent, and mixtures thereof.
21. The process according to claim 20, wherein the ethereal solvent is selected from the group consisting of dimethyl ether, diethyl ether, ethyl methyl ether, methyl-t-butyl ether, tetrahydrofuran, and 1,4-dioxane.
22. The process according to claim 20 wherein the alcoholic solvent is selected from the group consisting of methanol, ethanol, propanol, and butanol.
23. The process according to claim 20, wherein the solvent is a mixture of methyl-t-butyl ether and ethanol.
24. Crystalline polymorph form-Mi of cabozantinib free base.
25. The compound of claim 24, which has an X-ray powder diffraction pattern with a significant peak at about a 2Θ value of 11.8 (±) 0.2°.
26. Crystalline polymorph form-M2 of cabozantinib free base.
27. The compound of claim 26, which has an X-ray powder diffraction pattern with significant peaks at about 2Θ values of 12.6, 14.1, 18.5, 22.1, 23.2, 24.1, and 29.0 (±) 0.2°.
28. Crystalline polymorph form-M3 of cabozantinib free base.
29. The compound of claim 28, which has an X-ray powder diffraction pattern with significant peaks at about 2Θ values of 15.5, 17.7, 19.6, and 21.1 (±) 0.2°.
30. A process for the preparation of crystalline cabozantinib (S)-malate form N-l comprising the steps of:
a) providing cabozantinib base and (S)-malic acid in a first solvent to create a reaction mass;
b) adding a second solvent to the reaction mass;
c) seeding form N-l of cabozantinib (S)-malate; and
d) isolating the cabozantinib (S)-malate form N-l .
31. The process according to claim 13, wherein first solvent is polar.
32. The process according to claim 32 wherein the first solvent is selected from the group consisting methanol, ethanol, propanol, butanol, ethyl acetate, acetone, acetonitrile, dichloromethane, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, 1,4- dioxane, water, and mixtures thereof.
33. The process according to claim 30, wherein the second solvent is a nitrile solvent.
34. The process according to claim 33, wherein the nitrile solvent is acetonitrile.
PCT/IB2015/053765 2014-05-23 2015-05-22 Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base WO2015177758A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/313,191 US9815789B2 (en) 2014-05-23 2015-05-22 Polymorphs of cabozantinib (S)-malate and cabozantinib free base
EP15728635.2A EP3145913A1 (en) 2014-05-23 2015-05-22 Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2561/CHE/2014 2014-05-23
IN2561CH2014 2014-05-23

Publications (1)

Publication Number Publication Date
WO2015177758A1 true WO2015177758A1 (en) 2015-11-26

Family

ID=53385701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/053765 WO2015177758A1 (en) 2014-05-23 2015-05-22 Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base

Country Status (3)

Country Link
US (1) US9815789B2 (en)
EP (1) EP3145913A1 (en)
WO (1) WO2015177758A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018104954A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Process for the preparation of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate and its polymorphs thereof
WO2018218233A1 (en) * 2017-05-26 2018-11-29 Exelixis, Inc. Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
WO2020057622A1 (en) * 2018-09-20 2020-03-26 苏州科睿思制药有限公司 Cabozantinib malate crystal form, preparation method therefor and use thereof
WO2020075196A1 (en) * 2018-10-11 2020-04-16 Cipla Limited Polymorphs of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (s)- malate, methods of production and pharmaceutical uses thereof
US10980792B2 (en) 2016-09-12 2021-04-20 Zhuhai Beihai Biotech Co., Ltd. Formulations of Cabozantinib
IT202000027678A1 (en) 2020-11-18 2022-05-18 Indena Spa CABOZANTINIB-(S)-MALATO AMORPHOUS SOLID DISPERSIONS AND PROCESSES FOR THEIR PREPARATION
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116808044A (en) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 Salts of kinase inhibitors and compositions thereof
TW202302597A (en) * 2021-03-10 2023-01-16 美商米拉蒂醫療公司 Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
CN115215797B (en) * 2021-04-15 2024-04-12 成都苑东生物制药股份有限公司 Novel crystal form of cabozitinib malate and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579473B2 (en) 2003-09-26 2009-08-25 Exelixis, Inc. c-Met modulators and methods of use
WO2010083414A1 (en) * 2009-01-16 2010-07-22 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579473B2 (en) 2003-09-26 2009-08-25 Exelixis, Inc. c-Met modulators and methods of use
WO2010083414A1 (en) * 2009-01-16 2010-07-22 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3145913A1 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980792B2 (en) 2016-09-12 2021-04-20 Zhuhai Beihai Biotech Co., Ltd. Formulations of Cabozantinib
WO2018104954A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Process for the preparation of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate and its polymorphs thereof
US11261160B2 (en) 2016-12-07 2022-03-01 Msn Laboratories Private Limited, R&D Center Process for the preparation of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2S)-hydroxybutanedioate and its polymorphs thereof
AU2018272088B2 (en) * 2017-05-26 2022-06-16 Exelixis, Inc. Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-N'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
AU2018272088C1 (en) * 2017-05-26 2022-09-22 Exelixis, Inc. Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-N'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
US11731941B2 (en) 2017-05-26 2023-08-22 Exelixis, Inc. Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
CN110621662B (en) * 2017-05-26 2023-06-23 埃克塞里艾克西斯公司 Crystalline solid form of salt, preparation process and use method
EA039654B1 (en) * 2017-05-26 2022-02-22 Экселиксис, Инк. Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorphenyl)cyclopropane-1,1-dicarboxamide, processes for making and methods of use
CN110621662A (en) * 2017-05-26 2019-12-27 埃克塞里艾克西斯公司 Crystalline solid form of a salt, process for preparation and method of use
US11279675B2 (en) 2017-05-26 2022-03-22 Exelixis, Inc. Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
WO2018218233A1 (en) * 2017-05-26 2018-11-29 Exelixis, Inc. Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
CN112638880B (en) * 2018-09-20 2022-03-25 苏州科睿思制药有限公司 Cabotinib malate crystal form and preparation method and application thereof
WO2020057622A1 (en) * 2018-09-20 2020-03-26 苏州科睿思制药有限公司 Cabozantinib malate crystal form, preparation method therefor and use thereof
CN112638880A (en) * 2018-09-20 2021-04-09 苏州科睿思制药有限公司 Cabotinib malate crystal form and preparation method and application thereof
WO2020075196A1 (en) * 2018-10-11 2020-04-16 Cipla Limited Polymorphs of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (s)- malate, methods of production and pharmaceutical uses thereof
IT202000027678A1 (en) 2020-11-18 2022-05-18 Indena Spa CABOZANTINIB-(S)-MALATO AMORPHOUS SOLID DISPERSIONS AND PROCESSES FOR THEIR PREPARATION
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Also Published As

Publication number Publication date
EP3145913A1 (en) 2017-03-29
US9815789B2 (en) 2017-11-14
US20170096395A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
US9815789B2 (en) Polymorphs of cabozantinib (S)-malate and cabozantinib free base
US11472773B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
US11149017B2 (en) Solid state forms of apalutamide
EP2603503B1 (en) Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
AU2015254949A1 (en) Novel polymorphic forms of Vortioxetine and its pharmaceutically acceptable salts
US20210024506A1 (en) Polymorphic forms of afatinib free base and afatinib dimaleate
US20180282351A1 (en) Amorphous Ixazomib Citrate
WO2016016766A2 (en) A process for the preparation of isavuconazonium or its salt thereof
JP2021105003A (en) Process for preparing polymorph and quinazolinyl derivative
WO2019003249A1 (en) Polymorphic forms of baricitinib
US11390637B2 (en) Salts of antiviral phosphonate analogues and process for preparation thereof
WO2015049698A2 (en) Process for regorafenib
EP2598147A1 (en) N-methylformamide solvate of dasatinib
KR20160126697A (en) Novel crystalline varenicline oxalate hydrate, preparation method thereof, and pharmaceutical composition comprising same
WO2018042320A1 (en) Salts of betrixaban and processes for preparation thereof
US20180030038A1 (en) Polymorphic Forms of Afatinib Dimaleate
CA2811912A1 (en) Novel polymorphs of febuxostat
US20200407382A1 (en) Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
CN109476610B (en) Salt and polymorphic substance of phenyl pyrimidone compound, and pharmaceutical composition and application thereof
AU2010299484A1 (en) Polymorphs of sorafenib acid addition salts
JP2019529410A (en) Method for producing pure and stable crystalline raltegravir potassium type 3
US20210040031A1 (en) Process for the preparation of Safinamide Mesylate intermediate
WO2024194828A1 (en) Solid forms of roxadustat with camphorsulfonic acid
JP2021531329A (en) Maleate of benzothiophene compound, its crystalline form and its use
KR20160143407A (en) Novel varenicline mucate, crystalline form thereof, and method of preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15728635

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15313191

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015728635

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015728635

Country of ref document: EP